1 / 40

Peptic Ulcer

Peptic Ulcer. Chaohui Yu ych623@sina.com 13957161659. Suggested readings. 消化性溃疡 , 内科学第二版 , 人民卫生出版社 ,434-445 Acid peptic disease, Cecil medcine,24 th edition,886-895 Peptic ulcer disease, Lancet, 2009; 374: 1449-1461 Helicobacter pylori infection, N Engl J Med,2010;363;1597-1604.

chayton-pereyra
Télécharger la présentation

Peptic Ulcer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Peptic Ulcer Chaohui Yu ych623@sina.com 13957161659

  2. Suggested readings • 消化性溃疡,内科学第二版,人民卫生出版社,434-445 • Acid peptic disease, Cecil medcine,24th edition,886-895 • Peptic ulcer disease, Lancet, 2009; 374: 1449-1461 • Helicobacter pylori infection, N Engl J Med,2010;363;1597-1604

  3. The self-digestion of GI mucosa • caused by gastric acid and pepsin • The rate is 10% in population

  4. Why does the ulcer happen?- normal defense Bicarbonate Acid, pepsine mucus layer epithelial cell submucosa

  5. Defensive barrier of gastric and duodenal mucosa mucus barrier physical defense chemical counteraction • mucosal barrier • quick refreshment of • epithelial cell • abundant circulation of blood • nutrition factor: PGE1,EGF • intercellular tight junction • abundant submucosal • blood vessel • HCO3- counteracts H+

  6. Acid, pepsine attack factors defence factors Balance in attack and defence

  7. Mucosal damage Pathogenesy of PU • Acid and Pepsine • Helicobacter pylori • NSAIDs • Motility disturbance • Stress • Systemic inflammatory disorders • Ischemia • Hypergastrinemic Syndromes • Hyperhistaminic Syndromes • Anastomotic or marginal Ulceration • Alcohol • Tobacco defence attack

  8. Maximum activity of enzyme(%) 100 80 60 40 20 0 1 2 3 4 Gastric fluid pH Pathogenesy of PU—Acid & Pepsine Pepsine • rely on Acid • no acid,no ulcer • parietal cell mass 2 4 • parietal sensibility • feedback suppression • vagal tone

  9. Pathogenesy of PU —Helicobacter Pylori • Biology • bostrychoid,have flegalla, • microamount requirement of oxygen • urase: urea NH3 • Vac A, Cag A • Evidence-based medicine • high positive rate of HP in PU • the eradication of Hp facilitate the healing of PU • the eradication of Hp degrades the recurrence of PU

  10. 2005年10月

  11. Pathogenesy of PU—Helicobacter Pylori • The colonization factor of HP • bostrychoid,have flegalla • urase • especial adherence factor • Invasive factor • urase ammoniacal toxicity • Vac A, Cag A and • phosphatidase A1 • chemotact and activate inflammatory cell • antigen imitate • Two theory: • hypothesis of leaking roof • gastrin-link hypothesis • D cell & somatostatin

  12. Infection with H. pylori results in anacute inflammatory reaction Epithelial cell O2 radicals IL-8 Proteolyticenzymes Polymorph

  13. Increasing proportion of H. pylori-negative ulcers 1995–2000 2000 1995 13% 33% 67% 87% H. pylori-negative gastroduodenal ulcers H. pylori-positive gastroduodenal ulcers Juhasz, Gut 2001; 49: A64.

  14. guard gastric and duodenal mucosa Pathogenesy of PU— non-steroidal anti-inflammatory drugs, NSAID Arachidonic acid Cox1 Cox2 cycloxygenase antiinflammatory analgesia gastrointestinal damage nephrotoxicity X The synergistic affection of Hp and NSAID prostaglandin Maintain the function of kidney and platelet Inflammation、pain

  15. PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  16. + Pathogenesis of NSAID-induced ulcers PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins NSAIDs Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  17. + Pathogenesis of NSAID-induced ulcers PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins NSAIDs Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  18. + Pathogenesis of NSAID-induced ulcers PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins NSAIDs Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  19. + Pathogenesis of NSAID-induced ulcers PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins NSAIDs Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  20. + Pathogenesis of NSAID-induced ulcers PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins NSAIDs Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  21. + Pathogenesis of NSAID-induced ulcers PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins NSAIDs Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  22. + Pathogenesis of NSAID-induced ulcers PROTECTIVE FACTORS AGGRESSIVE FACTORS Prostaglandins NSAIDs Acid + pepsin H. pylori Mucus layer Bicarbonate Surface epithelial cells Mucosal blood supply Seager & Hawkey, BMJ 2001; 323: 1236–9.

  23. Ulcers related to NSAID use1995–2000 2000 1995 17% 31% 83% 59% NSAID-related ulcers Ulcers not related to NSAID use Juhasz, Gut 2001; 49: A64.

  24. Aspirin correlated ulcer Large GU, which healed in 14Wk after stopping aspirin use Deep GU unhealed for 5 years with continued aspirin abuse Large DU, which healed after stopping aspirin

  25. Location • DU: bulbar zone,antetheca • GU:lesser curvature side of sinus ventriculi,gastric corner • Especial denomination • complex ulcer: DU+GU • multiple ulcer: ≥two • two symmetria ulcers • enormous ulcer • DU>2cm,GU>3cm

  26. Clinical manifestation—upper GI symptoms • Chronicity、periodicity、rhythmic • Pain • DU：pain in hanger/hypnalgia， • remittence after the meal • pain- foodintake-remittence • GU：pain after the meal • foodintake-pain-remittence • location/property • Other dyspepsia symptoms

  27. Especial type of ulcer • Symptomless PU：15-35%，see a doctor after the appearance of the complications • PU in olders：most of superior positional/enormous ulcer ,often atypical symptoms • Complex ulcer：DU often happens earlier than GU, often atypical symptoms • Ulcer of pyloric canal：more gastric acid、bad curative effect、more complications • Post bulbar ulcer：night pain、radiating pain、more complications， bad curative effect. Difficult curable ulcer

  28. Differential diagnosis of symptoms Chronic gastritis/functional dyspepsia •   have symptoms，but no evidence Chronic cholecystitis/cholelithiasis •   the discrimination is difficult，oily food，BUS Castric carcinoma •    the discrimination is difficult in symptoms,gastroscope and pathologicalexamination are critical • atypical+multiple+more • complications+diarrhea Hookworm infection Gastrin adenoma

  29. Diagnosis—the existence of ulcer is true or untrue X –ray examination • Direct sign：niche sign • Indirect sign：spasmus、irritation • tenderness、deformation Gastroscopy：focus lesions+biopsy +Hp examination •  Active stage (A1,A2) •  Healing stage(H1,H2) •  Scar stage(S1,S2) A1 H1 S2

  30. Diagnosis—Hp infection is yes or no? virulence—need taking gastric mucosa • (RUT): ammine • Histological examination • Cultivation • PCR Non –virulent examination—not need taking gastric mucosa • Breath test • Serology • Hp stool antigen Urase based test: RUT、UBT

  31. Diagnose-if have complication upper GI hemorrhage (UGIH) •   the most common complication •   the first symptom of hemorrhage by • 10%-20% ulcer • activity symptom before hemorrhage • perforation •    acute perforation ：acute diffuse peritonitis •    penetrability perforation ： lesser bursa omentalis • subacute perforation pyloric obstruction：functionality/parenchymatous obstruction canceration：warning sings and symptoms • chronic patient history age>45(GU) • symptom has changed recently and curative effect badly • the appearance of hemorrhage :stool OB (+), • anemia • emaciation

  32. PU cure-purpose Eliminate cause of a disease、relieve symptom、heal ulcer、prevent recurrence、avoid complication defend attack Factitiousness intervention to speed up ulcer healing

  33. PU cure—degrade gastric acid Antacid：counteract gastric acid obviously rebound Acid-reducing Drugs ：H2RA，PPI H+ Omeprazole Lansoprazole pantoprazole Rabeprazole PPI DU:4-6 Wk GU:6-8 Wk Cimetidine Famotidine Nizatidine Ranitidine H2RA Ach Histamine Gastrin

  34. PU cure—Eradication Hp Program • Trigeminy with the core of PPI • PPI+(Clarithromycin/amoxicillin )+(furazlidone /metronidazole), Bid, 7-14d • Trigeminy with the core of bismuth • To object: blind medication ,single/ double • medication Re-examination ? •  Eradication:after course of treatment to • end for 4 weeks,HP Negative • Generally do not request re-examination

  35. Influence of successful eradication of H. pylori on ulcer healing Review of 60 trials; 4329 patients Ulcer healing rate according to post-treatment H. pylori status ***95 **88 H. pylori eradicated H. pylori persisted 100 76 73 **p<0.01 ***p<0.001 Healing rate (%) 0 Gastric ulcer Duodenal ulcer Treiber & Lambert, Gastroenterol 1998; 93: 1080–4.

  36. H. pylori eradication reduces recurrence in gastric ulcer 100 Non-eradicated H. pylori infection Eradicated H. pylori infection 80 60 Gastric ulcer recurrence (%) 40 20 0 Labenz Sung Labenz Karita Seppälä & Borsch et al. & Borsch et al. et al. (n=11) (n=19) (n=18) (n=4) (n=42) Labenz Sung Labenz Karita Seppälä & Borsch et al. & Borsch et al. et al. (n=16) (n=26) (n=32) (n=26) (n=10) Hopkins et al., Gastroenterol 1996; 110: 1244–52.

  37. Eradication of H. pylori almost eliminates duodenal ulcer recurrence H. pylori + ve H. pylori – ve ***96 ***95 ***95 ***92 100 58 Patients in remission (%) 40 30 25 0 0 Months 6 12 18 24 ***p<0.001 Huang et al., Am J Gastroenterol 1996, 91: 1914.

  38. The treatment of complication Peptic Ulcer Hemorrhage

  39. THANK YOU

More Related